John Taylor was appointed Idera’s Chief Executive Officer and a member of the Board of Directors in 2022, following the Company’s merger with Aceragen. He was the Co-Founder, President, and CEO of Aceragen as well as a member of the Board of Directors. He has extensive experience in the orphan and rare disease field, having spent a significant portion of his career developing therapeutic products in this area.
Prior to Aceragen, Mr. Taylor co-founded and was President and CEO of Spyryx Biosciences, a company he spun out of UNC-Chapel Hill to develop inhaled peptides as a treatment for cystic fibrosis. Under his leadership, Spyryx raised $23 million in venture capital with a top syndicate of investors, executed a $5 million development award with the Cystic Fibrosis Foundation, and advanced the lead program into the clinic.
Previously, Mr. Taylor was Vice President, Corporate Development with Synageva BioPharma, a biotechnology company developing enzyme replacement therapies for untreated lysosomal storage disorders. He played key roles in establishing Synageva’s product portfolio and in taking the company public via a reverse merger with Trimeris. Earlier, Mr. Taylor was the Vice President, Business Development for Javelin Pharmaceuticals and a senior business development leader with Eurand Pharmaceuticals.
Mr. Taylor holds a BS in Biological Sciences from Clemson University and an MS in Technology Management from the University of Pennsylvania.